proxyvotesnow.com

Home › Companies › REVANCE THERAPEUTICS INC. › 2023-2024

REVANCE THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 02 October 2026.

  • 7Reported items
  • 195Asset managers
  • 916Fund votes
  • 2024-05-01Meeting date

Proxy season: 2023-2024

Explore REVANCE THERAPEUTICS INC. in the interactive database Compare manager voting policies

How asset managers voted at the REVANCE THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 195 asset managers that disclosed a REVANCE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of REVANCE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval of, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement..

SECTION 14A SAY-ON-PAY VOTES

Combines 7 wordings of this item as funds reported it.

81% fund support · no official result

FOR 81%AGAINST 19%

The 184 asset managers below cast 81% of the shares they voted on this item FOR (63,531,187 for, 15,259,123 against).

FOR: 63,531,187 (80.6%)AGAINST: 15,259,123 (19.4%)ABSTAIN: 14,719 (0.0%)NOT VOTED: 9,000 (0.0%)
Largest asset managers voting on “Approval of, on an advisory basis, the compensation of the Company's named executive officers as disclosed in ” at REVANCE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group21,329,7270 00For
NEW ECONOMY FUND6,334,3830 00For
FRANKLIN ADVISERS INC39,3776,143,419 00Against
BlackRock5,250,47418,505 00For
Palo Alto Investors LP5,237,2840 00For
Vanguard4,968,1870 00For
Polar Capital Holdings Plc3,873,1690 00For
FRANKLIN STRATEGIC SERIES03,030,752 00Against
Federated Hermes2,780,5570 00For
JPMorgan8,6441,855,348 00Against
State Street1,688,708477 00For
Rubric Capital Management LP1,675,1340 00For
CIBC Asset Management Inc1,667,1180 00For
Charles Schwab1,407,0170 00For
BAMCO INC /NY/0945,813 00Against
Northern Trust805,5566,716 00For
SUVRETTA CAPITAL MANAGEMENT, LLC800,0000 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)0775,832 00Against
PERCEPTIVE ADVISORS LLC600,0000 00For
RICE HALL JAMES & ASSOCIATES, LLC10,126552,901 00Against
HighTower Advisors, LLC406,9270 00For
Nuveen355,5550 00For
UBS174,667134,306 00For
BLAIR WILLIAM & CO/IL292,7730 00For
SCHRODER INVESTMENT MANAGEMENT GROUP0288,726 00Against

Showing the 25 largest of 184 asset managers. See all 184 in the interactive database.

2. Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATED

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 54 asset managers below cast 99.9% of the shares they voted on this item FOR (31,645,047 for, 29 against).

FOR: 31,645,047 (100.0%)AGAINST: 29 (0.0%)ABSTAIN: 8,096 (0.0%)
Largest asset managers voting on “Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public acc” at REVANCE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group7,384,1920 00For
NEW ECONOMY FUND6,334,3830 00For
Vanguard4,734,1110 00For
FRANKLIN STRATEGIC SERIES3,030,7520 00For
BlackRock2,773,9000 00For
JPMorgan1,739,3930 00For
Federated Hermes1,388,5800 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)775,8320 00For
Charles Schwab703,4770 00For
Fidelity278,7900 00For
VALUE LINE CAPITAL APPRECIATION FUND INC274,2050 00For
AIG/SunAmerica254,0330 00For
TIAA243,4560 00For
State Street238,89829 00For
Equitable228,0040 00For
Jackson National169,9810 00For
Columbia Threadneedle161,5400 00For
QUANTITATIVE MASTER SERIES LLC154,2150 00For
Lincoln Financial110,4770 00For
Nushares ETF Trust100,0010 00For
ProShares56,1090 00For
SEI46,5690 00For
Northern Lights Fund Trust IV39,5850 00For
Northern Trust38,9480 00For
Global X35,8310 00For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

3. Election of Directors: Angus C. Russell

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 95%

The 53 asset managers below cast 100% of the shares they voted on this item FOR (30,238,974 for, 0 against).

FOR: 30,238,974 (94.9%)ABSTAIN: 1,619,503 (5.1%)
Largest asset managers voting on “Election of Directors: Angus C. Russell” at REVANCE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group7,384,1920 00For
NEW ECONOMY FUND6,334,3830 00For
Vanguard4,734,1110 00For
FRANKLIN STRATEGIC SERIES3,030,7520 00For
BlackRock2,773,9000 00For
JPMorgan1,739,3930 00For
Federated Hermes1,388,5800 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)00 775,8320Abstain
Charles Schwab703,4770 00For
Fidelity278,7900 00For
VALUE LINE CAPITAL APPRECIATION FUND INC274,2050 00For
AIG/SunAmerica00 254,0330Abstain
MUTUAL FUND SERIES TRUST245,0000 00For
TIAA243,4560 00For
State Street238,6060 3210For
Equitable139,2040 88,8000For
Jackson National00 169,9810Abstain
Columbia Threadneedle161,5400 00For
QUANTITATIVE MASTER SERIES LLC154,2150 00For
Lincoln Financial71,1000 39,3770For
Nushares ETF Trust100,0010 00For
ProShares00 56,1090Abstain
SEI46,5690 00For
Northern Trust38,9480 00For
Global X35,8310 00For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

4. Election of Directors: Olivia C. Ware

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 95%

The 53 asset managers below cast 100% of the shares they voted on this item FOR (30,296,190 for, 0 against).

FOR: 30,296,190 (95.1%)ABSTAIN: 1,562,287 (4.9%)
Largest asset managers voting on “Election of Directors: Olivia C. Ware” at REVANCE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group7,384,1920 00For
NEW ECONOMY FUND6,334,3830 00For
Vanguard4,734,1110 00For
FRANKLIN STRATEGIC SERIES3,030,7520 00For
BlackRock2,773,9000 00For
JPMorgan1,739,3930 00For
Federated Hermes1,388,5800 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)00 775,8320Abstain
Charles Schwab703,4770 00For
Fidelity278,7900 00For
VALUE LINE CAPITAL APPRECIATION FUND INC274,2050 00For
AIG/SunAmerica00 254,0330Abstain
MUTUAL FUND SERIES TRUST245,0000 00For
TIAA243,4560 00For
State Street238,6060 3210For
Equitable139,2040 88,8000For
Jackson National00 169,9810Abstain
Columbia Threadneedle161,5400 00For
QUANTITATIVE MASTER SERIES LLC154,2150 00For
Lincoln Financial71,1000 39,3770For
Nushares ETF Trust100,0010 00For
ProShares00 56,1090Abstain
SEI46,5690 00For
Northern Trust38,9480 00For
Global X35,8310 00For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

5. Election of Directors: Julian S. Gangolli

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.6%

The 52 asset managers below cast 100% of the shares they voted on this item FOR (31,516,570 for, 0 against).

FOR: 31,516,570 (99.7%)ABSTAIN: 96,907 (0.3%)
Largest asset managers voting on “Election of Directors: Julian S. Gangolli” at REVANCE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group7,384,1920 00For
NEW ECONOMY FUND6,334,3830 00For
Vanguard4,734,1110 00For
FRANKLIN STRATEGIC SERIES3,030,7520 00For
BlackRock2,773,9000 00For
JPMorgan1,739,3930 00For
Federated Hermes1,388,5800 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)775,8320 00For
Charles Schwab703,4770 00For
Fidelity278,7900 00For
VALUE LINE CAPITAL APPRECIATION FUND INC274,2050 00For
AIG/SunAmerica254,0330 00For
TIAA243,4560 00For
State Street238,9160 110For
Equitable139,2040 88,8000For
Jackson National169,9810 00For
Columbia Threadneedle161,5400 00For
QUANTITATIVE MASTER SERIES LLC154,2150 00For
Lincoln Financial110,4770 00For
Nushares ETF Trust100,0010 00For
ProShares56,1090 00For
SEI46,5690 00For
Northern Trust38,9480 00For
Global X35,8310 00For
New York Life34,3190 00For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

6. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESCOMPENSATION

Combines 2 wordings of this item as funds reported it.

48.2% fund support · no official result

FOR 48.2%AGAINST 51.8%

The 5 asset managers below cast 48.2% of the shares they voted on this item FOR (228,044 for, 245,000 against).

FOR: 228,044 (48.2%)AGAINST: 245,000 (51.8%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy ” at REVANCE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST0245,000 00Against
Opaleye Management Inc.228,0000 00For
Orion Porfolio Solutions, LLC220 00For
Orion Portfolio Solutions, LLC220 00For
Stonepine Capital Management, LLC00 00--

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

0.5% fund support · no official result

AGAINST 99.5%

The 4 asset managers below cast 0.5% of the shares they voted on this item FOR (9,828 for, 2,190,919 against).

FOR: 9,828 (0.4%)AGAINST: 2,190,919 (99.6%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at REVANCE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
JPMorgan01,912,907 00Against
DCF Advisers, LLC0263,372 00Against
ALGERT GLOBAL LLC014,640 00Against
ESSEX INVESTMENT MANAGEMENT CO LLC9,8280 00For

Largest REVANCE THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of REVANCE THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting.

Top REVANCE THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager Shares voted
1Capital Group 21,329,727
2NEW ECONOMY FUND 6,334,383
3FRANKLIN ADVISERS INC 6,182,796
4BlackRock 5,268,979
5Palo Alto Investors LP 5,237,284
6Vanguard 4,968,187
7Polar Capital Holdings Plc 3,873,169
8FRANKLIN STRATEGIC SERIES 3,030,752
9Federated Hermes 2,780,557
10JPMorgan 1,863,992

Shown as share counts, not percentages: no shares-outstanding figure has been matched to REVANCE THERAPEUTICS INC. for the 2023-2024 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At REVANCE THERAPEUTICS INC.'s shareholder meeting held 2024-05-01, in the 2023-2024 proxy season, 195 asset managers reported how they voted in their SEC Form N-PX filings, covering 916 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — Approval of, on an advisory basis, the compensation of the Company's named executive officers… — the reporting funds cast 81% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

REVANCE THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).